Comment On: Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma.
作者信息
Liu Zhi-Peng, Dai Hai-Su, Su Xing-Xing, Yang Yi-Shi, Yin Xian-Yu, Chen Zhi-Yu
机构信息
Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Amy Medical University), Chongqing, China.
出版信息
Ann Surg Open. 2023 Apr 17;4(2):e273. doi: 10.1097/AS9.0000000000000273. eCollection 2023 Jun.
Abstract
摘要
相似文献
1
Comment On: Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma.评论：前瞻性II期试验验证了新辅助化疗对胰腺腺癌复发模式的影响。
Ann Surg Open. 2023 Apr 17;4(2):e273. doi: 10.1097/AS9.0000000000000273. eCollection 2023 Jun.
2
Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma.前瞻性 II 期临床试验验证了新辅助化疗对胰腺腺癌复发模式的影响。
Ann Surg. 2022 Nov 1;276(5):e502-e509. doi: 10.1097/SLA.0000000000004585. Epub 2020 Oct 19.
3
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015).随机 II 期研究：吉西他滨和 S-1 联合治疗与吉西他滨和白蛋白结合型紫杉醇纳米粒联合治疗用于可切除/交界可切除胰腺导管腺癌（PDAC-GS/GA-rP2，CSGO-HBP-015）新辅助化疗。
Trials. 2021 Aug 26;22(1):568. doi: 10.1186/s13063-021-05541-w.
4
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).可切除胰腺癌中辅助吉西他滨与新辅助吉西他滨/奥沙利铂加辅助吉西他滨的比较：一项随机多中心 III 期研究（NEOPAC 研究）。
BMC Cancer. 2011 Aug 10;11:346. doi: 10.1186/1471-2407-11-346.
5
Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma.胰腺癌的辅助和新辅助治疗。
Jpn J Clin Oncol. 2020 May 5;50(5):483-489. doi: 10.1093/jjco/hyaa018.
6
Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.新辅助化疗可使可切除胰腺癌产生显著的肿瘤反应且不增加发病率：一项前瞻性II期试验的结果
Ann Surg. 2008 Dec;248(6):1014-22. doi: 10.1097/SLA.0b013e318190a6da.
7
Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.吉西他滨和顺铂新辅助化疗用于可切除胰头腺癌的前瞻性II期试验
J Clin Oncol. 2008 May 20;26(15):2526-31. doi: 10.1200/JCO.2007.15.5556.
8
Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study.活性己糖相关化合物对可切除/边界可切除胰腺癌患者生存的疗效：一项双盲随机 II 期研究的研究方案。
Trials. 2022 Feb 12;23(1):135. doi: 10.1186/s13063-021-05934-x.
9
Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?可切除胰腺癌的新辅助治疗：是否到了进行 III 期试验的时间？
World J Gastroenterol. 2010 Oct 21;16(39):4883-7. doi: 10.3748/wjg.v16.i39.4883.
10
Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma.可切除及边界可切除胰腺腺癌新辅助放化疗联合或不联合全身化疗的疗效
Front Oncol. 2020 Sep 16;10:1461. doi: 10.3389/fonc.2020.01461. eCollection 2020.
本文引用的文献
1
Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma.前瞻性 II 期临床试验验证了新辅助化疗对胰腺腺癌复发模式的影响。
Ann Surg. 2022 Nov 1;276(5):e502-e509. doi: 10.1097/SLA.0000000000004585. Epub 2020 Oct 19.
Zotero 插件